日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

虽然并非适应症用药,但正中靶点:实施抗癌药物替代给药方案所需的证据

Overbeek, J K; Ter Heine, R; Verheul, H M W; Chatelut, E; Rudek, M A; Gurney, H; Plummer, R; Gilbert, D C; Buclin, T; Burger, D M; Bloemendal, H J; van Erp, N P

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies

索拉非尼剂量增加并非总是会导致晚期恶性肿瘤患者血压升高(即使血压正常)。

Karovic, S; Wen, Y; Karrison, T G; Bakris, G L; Levine, M R; House, L K; Wu, K; Thomeas, V; Rudek, M A; Wright, J J; Cohen, E E W; Fleming, G F; Ratain, M J; Maitland, M L

Pharmacotherapy in cancer patients with HIV/AIDS

艾滋病毒/艾滋病合并癌症患者的药物治疗

Beumer, J H; Venkataramanan, R; Rudek, M A

Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer

双硫仑治疗非转移性复发性前列腺癌男性患者的药效学研究

Schweizer, M T; Lin, J; Blackford, A; Bardia, A; King, S; Armstrong, A J; Rudek, M A; Yegnasubramanian, S; Carducci, M A

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.

组蛋白去乙酰化酶抑制剂恩替诺特联合 13-顺式维甲酸治疗实体瘤患者的 I 期研究

Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci M A, Rudek M A

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

索拉非尼治疗复发难治性急性白血病患者的药效学研究

Pratz, K W; Cho, E; Levis, M J; Karp, J E; Gore, S D; McDevitt, M; Stine, A; Zhao, M; Baker, S D; Carducci, M A; Wright, J J; Rudek, M A; Smith, B D